Immune Complexes and the Risk of CVD in Type 1 Diabetes

Overview

Journal Diabetes

Specialty Endocrinology

Date 2019 Jun 21

PMID 31217176

Citations 5

Authors

Maria F Lopes-Virella

Ionut Bebu

Kelly J Hunt

Gabriel Virella

Nathaniel L Baker

Barbara Braffett

Xiaoyu Gao

John M Lachin

Affiliations

Soon will be listed here.

Abstract

We investigated whether the composition of modified forms of LDL in circulating immune complexes (LDL-ICs) was associated with cardiovascular disease (CVD) outcomes, including any CVD, major adverse cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), and coronary artery disease, in type 1 diabetes (T1D). Our results demonstrate that the baseline levels of oxidized LDL (oxLDL), MDA-modified LDL (MDA-LDL), and advanced glycosylation-modified LDL (AGE-LDL) in circulating ICs were associated with the four CVD outcomes in unadjusted models, and adjustment by age and mean HbA only resulted in minimal reduction of these associations. After adjustments were made for other cardiovascular risk factors, particularly LDL cholesterol, oxLDL-IC and MDA-LDL-IC remained independently associated with the risk of CVD, and oxLDL-IC was independently associated with the risk of MACCE and MI. In the majority of cases, the baseline levels of modified LDL-IC (measured many years before the occurrence of any CVD event) were associated with the risk of CVD over a 25-year period even after adjustment for other risk factors (including LDL cholesterol). Therefore, modified LDL biomarkers may help identify patients with T1D at high risk for MACCE and CVD events very early in the evolution of the disease, before other signals of disease are apparent.

Citing Articles

Recognition of Oxidized Lipids by Macrophages and Its Role in Atherosclerosis Development.

Mushenkova N, Bezsonov E, Orekhova V, Popkova T, Starodubova A, Orekhov A Biomedicines. 2021; 9(8).

PMID: 34440119 PMC: 8389651. DOI: 10.3390/biomedicines9080915.

The Problem of Abnormal Body Weight and Dyslipidemia as Risk Factors for Cardiovascular Diseases in Children and Adolescents with Type 1 Diabetes.

Noras K, Rusak E, Jarosz-Chobot P J Diabetes Res. 2021; 2021:5555149.

PMID: 34395631 PMC: 8355997. DOI: 10.1155/2021/5555149.

Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities.

OBrien S, Neylon O, OBrien T Biomedicines. 2021; 9(7).

PMID: 34356890 PMC: 8301346. DOI: 10.3390/biomedicines9070826.

Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes.

Sveen K, Holte K, Svanteson M, Hanssen K, Nilsson J, Bengtsson E Diabetes Care. 2021; 44(6):1402-1409.

PMID: 33858856 PMC: 8247486. DOI: 10.2337/dc20-2089.

Realising the long-term promise of insulin therapy: the DCCT/EDIC study.

Nathan D Diabetologia. 2021; 64(5):1049-1058.

PMID: 33550441 DOI: 10.1007/s00125-021-05397-4.

References

Lopes-Virella M, Virella G, Orchard T, Koskinen S, Evans R, Becker D . Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999; 90(2):165-72. DOI: 10.1006/clim.1998.4631. View

. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999; 22(1):99-111. PMC: 2745938. DOI: 10.2337/diacare.22.1.99. View

Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M . Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001; 103(15):1955-60. DOI: 10.1161/01.cir.103.15.1955. View

Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T . C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med. 2001; 33(1):37-47. DOI: 10.3109/07853890109002058. View

Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K . Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002; 22(4):662-6. DOI: 10.1161/01.atv.0000012351.63938.84. View

Hulthe J, Fagerberg B . Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002; 22(7):1162-7. DOI: 10.1161/01.atv.0000021150.63480.cd. View

Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella M . Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002; 105(1):81-92. DOI: 10.1006/clim.2002.5269. View

Lopes-Virella M, Mironova M, Stephan E, Durazo-Arvizu R, Virella G . Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care. 2004; 27(4):908-13. DOI: 10.2337/diacare.27.4.908. View

. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care. 1992; 15(7):886-94. DOI: 10.2337/diacare.15.7.886. View

10.

Virella G, Thorpe S, Alderson N, Derrick M, Chassereau C, Rhett J . Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004; 45(10):1859-67. DOI: 10.1194/jlr.M400095-JLR200. View

11.

Amaki T, Suzuki T, Nakamura F, Hayashi D, Imai Y, Morita H . Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. Heart. 2004; 90(10):1211-3. PMC: 1768480. DOI: 10.1136/hrt.2003.018226. View

12.

Jenkins A, Rowley K, Lyons T, Best J, Hill M, Klein R . Lipoproteins and diabetic microvascular complications. Curr Pharm Des. 2004; 10(27):3395-418. DOI: 10.2174/1381612043383188. View

13.

Virella G, Derrick M, Pate V, Chassereau C, Thorpe S, Lopes-Virella M . Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol. 2005; 12(1):68-75. PMC: 540197. DOI: 10.1128/CDLI.12.1.68-75.2005. View

14.

Saad A, Virella G, Chassereau C, Boackle R, Lopes-Virella M . OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006; 47(9):1975-83. DOI: 10.1194/jlr.M600064-JLR200. View

15.

Virella G, Carter R, Saad A, Crosswell E, Game B, Lopes-Virella M . Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008; 127(3):394-400. PMC: 2601558. DOI: 10.1016/j.clim.2008.02.005. View

16.

Wang J, Hu B, Meng Y, Zhang C, Li K, Hui C . The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. Clin Biochem. 2009; 42(13-14):1352-7. DOI: 10.1016/j.clinbiochem.2009.05.016. View

17.

Lopes-Virella M, Hunt K, Baker N, Lachin J, Nathan D, Virella G . Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2010; 60(2):582-9. PMC: 3028359. DOI: 10.2337/db10-0915. View

18.

Lopes-Virella M, Baker N, Hunt K, Lachin J, Nathan D, Virella G . Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2010; 214(2):462-7. PMC: 3031663. DOI: 10.1016/j.atherosclerosis.2010.11.012. View

19.

Lopes-Virella M, Hunt K, Baker N, Virella G, Moritz T . The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012; 224(2):526-31. PMC: 4240617. DOI: 10.1016/j.atherosclerosis.2012.08.006. View

20.

Virella G, Colglazier J, Chassereau C, Hunt K, Baker N, Lopes-Virella M . Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74. DOI: 10.1080/15321819.2012.683500. View